This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Rani Therapeutics Holdings (NASDAQ: RANI) shocked the stock market on Friday as its shares soared 248% to close at $1.64, following a collaboration with Japan’s Chugai Pharmaceutical.RANI one-day stock price chart. Source: Google Finance Rani’s stock jumped 222% in the past month, driven by investor excitement over its RaniPill technology, a capsule that delivers biologic drugs orally, replacing injections. The surge followed news of a collaboration with Chugai Pharmaceutical to develop an oral formulation ...

Company Developments - Rani Therapeutics Holdings, Inc. (RANI) experienced a significant price increase of 303.48% to $1.9, attributed to a licensing agreement with Chugai Pharmaceutical potentially worth up to $1.09 billion, involving an oral drug and possibly extending to five drugs [1][7] - Artiva Biotherapeutics, Inc. (ARTV) saw a 148.74% rise to $6.89, linked to the FDA granting Fast Track Designation for its AlloNK® development targeting refractory rheumatoid arthritis, with promising trial results showing consistent B-cell depletion and favorable safety profiles [2][7] - Sunshine Biopharma, Inc. (SBFMW) had a 71.22% increase to $0.29, driven by investor optimism regarding potential breakthroughs in its anticancer research [3][7] - NextPlat Corp (NXPLW) rose by 55.52% to $0.1, possibly reflecting new contracts or technological advancements in mobile satellite services, with expansion into new markets impacting its business model and revenue streams [4] - XORTX Therapeutics Inc. (XRTX) experienced a 52.35% increase to $1.29, due to acquiring a renal anti-fibrotic therapeutic program from Vectus Biosystems, enhancing its clinical programs [5] Market Trends - Recent market trends indicate notable price changes among several companies, reflecting various factors driving investor interest, underscoring the dynamic nature of the stock market [6]

周五，Rani Therapeutics(RANI.US)飙升超265%，盘中一度熔断，股价创年内新高，报1.76美元。消息 面上，该公司宣布与中外制药Chugai达成高达10.85亿美元的合作协议，获得1000万美元预付款，并有 资格获得最高7500万美元技术转让与发展里程碑金、1亿美元销售里程碑金及个位数特许权使用费，同 时中外制药有权选择扩展至5个额外药物靶点。Rani Therapeutics主营生物制品口服递送技术，核心平台 RaniPill专注于口服抗体及罕见病药物开发，此次合作应用于中外制药的罕见病抗体项目，验证技术应 用价值。 ...

智通财经APP获悉，周五，Rani Therapeutics(RANI.US)飙升超265%，盘中一度熔断，股价创年内新 高，报1.76美元。消息面上，该公司宣布与中外制药Chugai达成高达10.85亿美元的合作协议，获得1000 万美元预付款，并有资格获得最高7500万美元技术转让与发展里程碑金、1亿美元销售里程碑金及个位 数特许权使用费，同时中外制药有权选择扩展至5个额外药物靶点。Rani Therapeutics主营生物制品口服 递送技术，核心平台RaniPill®专注于口服抗体及罕见病药物开发，此次合作应用于中外制药的罕见病 抗体项目，验证技术应用价值。 ...

Rani Therapeutics (Nasdaq: RANI) Makes Nasdaq Top Gainer on $1.085 Billion Pharma Collaboration News October 17, 2025- (Investorideas.com Newswire), a go-to investing platform covering biotech and medtech stocks releases a news and trading alert for Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs. The stock makes the Nasdaq top gainer list on a massive $1.085 Billion pharma deal. The stock is trading at $1.6 ...

Core Insights - Rani Therapeutics has entered into a licensing agreement with Chugai Pharmaceutical for an oral drug, with the potential to extend the deal to five additional drugs, which could increase the total deal value to $1.09 billion [1] Company Summary - The agreement allows Chugai Pharmaceutical to license an oral drug developed by Rani Therapeutics [1] - The potential extension of the deal to five drugs indicates a significant opportunity for Rani Therapeutics to expand its market presence and revenue [1] Financial Implications - The total deal value of $1.09 billion highlights the financial significance of the partnership for Rani Therapeutics [1]

Core Viewpoint - Rani Therapeutics has announced a private placement of Class A common stock and accompanying warrants, expected to generate approximately $60.3 million in gross proceeds, aimed at funding operations into 2028 and advancing its RaniPill® platform [1][3][4] Private Placement Details - The private placement will involve the issuance of 42,633,337 shares of Class A common stock at a price of $0.48 per share and pre-funded warrants at $0.4799 per warrant, with an exercise price of $0.0001 per share for the pre-funded warrants [5] - The accompanying warrants will allow the purchase of up to 125,000,004 shares of Class A common stock at an exercise price of $0.48 per share, exercisable upon stockholder approval [5][6] Use of Proceeds - Net proceeds from the private placement, along with an upfront payment of $10 million and an expected $18 million technology transfer milestone from Chugai Pharmaceuticals, will support the company's operations and pipeline development through 2028 [3][4] Strategic Partnerships - The financing is seen as a pivotal moment for Rani, combining its oral delivery technology with Chugai's expertise in antibody development, aiming to create transformative oral therapies for rare diseases [4][12] Investor Participation - The private placement was led by Samsara BioCapital, with participation from other investors including RA Capital Management and Anomaly, and includes a provision for Samsara and Anomaly to designate board members [6][7][8] Debt Conversion - Avenue Venture Opportunities Fund will convert $6 million of outstanding debt into 12,500,000 shares of Class A common stock and receive warrants on the same terms as other investors, reducing the company's debt obligations [9]

Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones and single digit royalties on product sales for the first license agreementChugai has the option to extend its rights to partner with Rani on up to 5 additional drug targets at similar deal terms bringing the total potential deal value to over $1 billionRani announced a $60.3 million private placement financing led by Samsara Bio ...

PART I. FINANCIAL INFORMATION This section presents the unaudited financial statements, management's analysis, market risk disclosures, and controls for the period [Financial Statements (Unaudited)](index=5&type=section&id=Item%201.%20Financial%20Statements%20(Unaudited)) Unaudited financials reveal a **$24.0 million net loss**, **$116.9 million accumulated deficit**, and **$9.2 million stockholders' deficit**, raising going concern doubts - The company has incurred recurring losses, including a net loss of **$24.0 million** for the six months ended June 30, 2025, and had an accumulated deficit of **$116.9 million**. As of June 30, 2025, cash, cash equivalents, and marketable securities totaled **$10.2 million**[32](index=32&type=chunk) - Management has concluded that based on available cash and the current operating plan, there is substantial doubt about the company's ability to continue as a going concern for one year after the financial statement issuance date[32](index=32&type=chunk)[33](index=33&type=chunk) Condensed Consolidated Balance Sheet Summary (in thousands) | Account | June 30, 2025 (Unaudited) | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $10,216 | $3,762 | | Marketable securities | $0 | $23,877 | | Total current assets | $11,073 | $29,744 | | Total assets | $16,898 | $36,634 | | **Liabilities & Equity** | | | | Total current liabilities | $20,623 | $19,891 | | Total liabilities | $26,051 | $33,141 | | Total stockholders' (deficit)/equity | ($9,153) | $3,493 | Condensed Consolidated Statements of Operations Summary (in thousands) | Metric | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | Contract revenue | $172 | $0 | | Research and development | $12,075 | $13,700 | | General and administrative | $10,615 | $12,857 | | Loss from operations | ($22,518) | ($26,557) | | Net loss | ($23,962) | ($28,140) | | Net loss per Class A share | ($0.40) | ($0.55) | Condensed Consolidated Statements of Cash Flows Summary (in thousands) | Cash Flow Activity | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | ($13,945) | ($18,431) | | Net cash provided by investing activities | $23,942 | $16,819 | | Net cash (used in)/provided by financing activities | ($3,543) | $262 | [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=24&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses severe liquidity, **going concern doubts**, Nasdaq non-compliance, and positive preclinical data - The company's existing capital resources are insufficient to initiate pivotal clinical trials, and there is substantial doubt about its ability to continue as a going concern for one year. Cash resources are not expected to be sufficient to meet operating needs beyond late September 2025 without additional funding[130](index=130&type=chunk)[173](index=173&type=chunk) - The company received non-compliance notices from Nasdaq for failing to meet the minimum bid price requirement of **$1.00 per share** and the minimum Market Value of Listed Securities (MVLS) of **$50 million**[114](index=114&type=chunk) - Recent financing activities include raising net proceeds of **$3.9 million** in May 2025 from a warrant exercise and gross proceeds of **$3.0 million** in July 2025 from a securities purchase agreement[111](index=111&type=chunk)[112](index=112&type=chunk) - Positive preclinical data was announced, demonstrating bioequivalence of orally delivered RT-114 (bispecific GLP-1/GLP-2 agonist) to subcutaneous injection, and successful oral delivery of semaglutide (GLP-1 agonist) via the RaniPill HC[116](index=116&type=chunk)[118](index=118&type=chunk) Comparison of Operating Expenses (in thousands) | Expense Category | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | Change | | :--- | :--- | :--- | :--- | | Research and development | $12,075 | $13,700 | (11.9)% | | General and administrative | $10,615 | $12,857 | (17.4)% | | **Total operating expenses** | **$22,690** | **$26,557** | **(14.6)%** | [Quantitative and Qualitative Disclosures About Market Risk](index=33&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company is a smaller reporting company and is not required to provide the information for this item - As a smaller reporting company defined by Rule 12b-2 of the Exchange Act, the company is not required to provide quantitative and qualitative disclosures about market risk[162](index=162&type=chunk) [Controls and Procedures](index=33&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded disclosure controls were effective as of June 30, 2025, with no material changes to internal controls - Based on an evaluation as of June 30, 2025, the Chief Executive Officer and Chief Financial Officer concluded that the company's disclosure controls and procedures were effective at a reasonable assurance level[163](index=163&type=chunk) - There were no changes in internal control over financial reporting during the three months ended June 30, 2025, that have materially affected, or are reasonably likely to materially affect, internal controls[164](index=164&type=chunk) PART II. OTHER INFORMATION This section covers legal proceedings, risk factors, equity sales, defaults, mine safety, and other disclosures [Legal Proceedings](index=34&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently a party to any legal proceedings that are expected to have a material adverse effect on its business - The company is not currently involved in any litigation or legal proceedings that management believes are likely to have a material adverse effect on the business[168](index=168&type=chunk) [Risk Factors](index=34&type=section&id=Item%201A.%20Risk%20Factors) Critical risks include **going concern doubts**, potential Nasdaq delisting, and international trade and supply chain disruptions - There is substantial doubt about the company's ability to continue as a going concern. Existing cash of **$10.2 million** as of June 30, 2025, is not sufficient to meet operating needs beyond late September 2025, and failure to raise additional capital could lead to ceasing operations or bankruptcy[170](index=170&type=chunk)[172](index=172&type=chunk)[173](index=173&type=chunk) - The company does not meet Nasdaq's continued listing requirements for minimum bid price and minimum market value of listed securities (MVLS), creating a risk of delisting, which would negatively impact stock liquidity and the ability to raise capital[181](index=181&type=chunk)[182](index=182&type=chunk)[183](index=183&type=chunk) - A new risk factor has been added regarding international trade policies, including tariffs and sanctions, which could adversely affect the business by increasing costs and disrupting the supply chain for raw materials and drug substances sourced from countries like China and Korea[186](index=186&type=chunk)[187](index=187&type=chunk)[188](index=188&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=38&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) There were no unregistered sales of equity securities during the period - None reported[192](index=192&type=chunk) [Defaults Upon Senior Securities](index=38&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) There were no defaults upon senior securities during the period - None reported[193](index=193&type=chunk) [Mine Safety Disclosures](index=38&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - Not applicable[194](index=194&type=chunk) [Other Information](index=38&type=section&id=Item%205.%20Other%20Information) The Board approved a cash retention program for executive officers and key employees on August 1, 2025 - On August 1, 2025, the Board approved a retention program for certain executive officers and key employees, providing cash payments equal to four months of their respective annual salaries[195](index=195&type=chunk) [Exhibits](index=39&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the report, including certifications by the Principal Executive and Financial Officers